Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Steam vs. pill: new study tests One-Time procedure for prostate troubles

NCT ID NCT07169773

Disease control Sponsor: khaled Abdelsattar Gad Ibrahim Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study compared two treatments for men with an enlarged prostate causing urinary symptoms. One group received a procedure called Rezum, which uses water vapor (steam) to shrink prostate tissue. The other group took a daily medication called tamsulosin. The trial enrolled 94 men and measured symptom scores, urine flow, and quality of life over 12 months. The goal was to see which approach works better and is safer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Rezum (water vapor thermal ablation) and tamsulosin
What this could lead to
If Rezum works better than tamsulosin, it could offer a one-time procedure to ease urinary symptoms from an enlarged prostate, reducing the need for daily pills.
What could go wrong
This is a small, completed trial with 94 men. Results may not apply to everyone, and Rezum is a procedure with risks like any surgery. It is not a cure; symptoms may return over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

94 people

The number who actually took part.

Started

May 2022

Finished

Jun 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 80 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. with prostate volumes of 30- 80 mL, 2. mild to mod LUTS 3. (maximum urinary flow rate \[Q max\] of \<15 mL/s 4. International Prostate Symptom Score \[IPSS\] of \>13) 5. PVR urine \< 250 ml Exclusion Criteria: 1. prostate cancer, 2. neurogenic bladder 3. urethral stricture, 4. urinary bladder stone 5. previous prostatic surgery

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate hyperplasia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

benign prostatic hyperplasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate hyperplasia

Contacts and locations

Locations

  • The Armed Forces College of Medicine (AFCM

    Cairo, Nozha, 4470351, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.